Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

Abstract Background Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine. Galcanezumab demonstrated early onset of effect in patients with migraine but it is unknown whether the same holds true for pat...

Full description

Bibliographic Details
Main Authors: Todd J. Schwedt, Dulanji K. Kuruppu, Yan Dong, Katherine Standley, Laura Yunes-Medina, Eric Pearlman
Format: Article
Language:English
Published: BMC 2021-03-01
Series:The Journal of Headache and Pain
Subjects:
Galcanezumab
Migraine
Preventive failure
Early onset
Calcitonin gene-related peptide
CGRP
Online Access:https://doi.org/10.1186/s10194-021-01230-w

Internet

https://doi.org/10.1186/s10194-021-01230-w

Similar Items